These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 20873592)

  • 1. [Expressions of 6 microRNAs in prostate cancer].
    Yin Y; Li M; Li H; Jiang Y; Cao LY; Zhang HF; Xu XC
    Zhonghua Nan Ke Xue; 2010 Jul; 16(7):599-605. PubMed ID: 20873592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression and significance of PCNA and p27 in benign prostate hypertrophy and prostate carcinoma].
    Lai JS; Xia Q; Zhang XB; Zhao GP; Xu SL; Zheng DS
    Zhonghua Zhong Liu Za Zhi; 2004 Aug; 26(8):476-8. PubMed ID: 15555337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer.
    Zhigang Z; Wenlu S
    Prostate; 2007 May; 67(6):653-60. PubMed ID: 17342746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNAs and prostate cancer.
    Coppola V; De Maria R; Bonci D
    Endocr Relat Cancer; 2010 Mar; 17(1):F1-17. PubMed ID: 19779034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer.
    Hermani A; Hess J; De Servi B; Medunjanin S; Grobholz R; Trojan L; Angel P; Mayer D
    Clin Cancer Res; 2005 Jul; 11(14):5146-52. PubMed ID: 16033829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer.
    Zhigang Z; Wenlv S
    Jpn J Clin Oncol; 2004 Jul; 34(7):414-9. PubMed ID: 15342669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secretagogin is a new neuroendocrine marker in the human prostate.
    Adolf K; Wagner L; Bergh A; Stattin P; Ottosen P; Borre M; Birkenkamp-Demtröder K; Orntoft TF; Tørring N
    Prostate; 2007 Apr; 67(5):472-84. PubMed ID: 17285592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer.
    Quek ML; Daneshmand S; Rodrigo S; Cai J; Dorff TB; Groshen S; Skinner DG; Lieskovsky G; Pinski J
    Urology; 2006 Jun; 67(6):1247-52. PubMed ID: 16697447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer.
    Zhong WD; Han ZD; He HC; Bi XC; Dai QS; Zhu G; Ye YK; Liang YX; Qin WJ; Zhang Z; Zeng GH; Chen ZN
    Oncology; 2008; 75(3-4):230-6. PubMed ID: 18852494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
    Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
    Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostatic adenocarcinoma in colorectal biopsy: clinical and pathologic features.
    Lane Z; Epstein JI; Ayub S; Netto GJ
    Hum Pathol; 2008 Apr; 39(4):543-9. PubMed ID: 18234278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression of cyclooxygenase-2 and vascular endothelial growth factor in human prostate cancer and its significance].
    Jin TX; Li XG; Wu WY; Piao DM; Feng JY; Sang J
    Zhonghua Nan Ke Xue; 2006 Mar; 12(3):207-10. PubMed ID: 16597032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications.
    Theodoropoulos VE; Tsigka A; Mihalopoulou A; Tsoukala V; Lazaris AC; Patsouris E; Ghikonti I
    Urology; 2005 Oct; 66(4):897-902. PubMed ID: 16230178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. alpha-Methylacyl coenzyme A racemase, Ki-67, and topoisomerase IIalpha in cystoprostatectomies with incidental prostate cancer.
    Santinelli A; Mazzucchelli R; Barbisan F; Lopez-Beltran A; Cheng L; Scarpelli M; Montironi R
    Am J Clin Pathol; 2007 Oct; 128(4):657-66. PubMed ID: 17875519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence.
    Seligson DB; Hongo F; Huerta-Yepez S; Mizutani Y; Miki T; Yu H; Horvath S; Chia D; Goodglick L; Bonavida B
    Clin Cancer Res; 2007 Oct; 13(20):6056-63. PubMed ID: 17947468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer antigen-1 as a potential novel marker for prostate cancer.
    Liu BQ; Wu YD; Li PH; Wei JX; Zhang T; Liu RL
    Asian J Androl; 2007 Nov; 9(6):821-6. PubMed ID: 17968469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dystroglycan expression is reduced during prostate tumorigenesis and is regulated by androgens in prostate cancer cells.
    Sgambato A; De Paola B; Migaldi M; Di Salvatore M; Rettino A; Rossi G; Faraglia B; Boninsegna A; Maiorana A; Cittadini A
    J Cell Physiol; 2007 Nov; 213(2):528-39. PubMed ID: 17516554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Changes in prostatic acid phosphatase, gamma-seminoprotein and prostate specific antigen after endocrine therapy for stage D2 prostate cancer].
    Akimoto S; Akakura K; Masai M; Isaka S; Shimazaki J
    Hinyokika Kiyo; 1990 Jul; 36(7):783-91. PubMed ID: 1700588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNAs and prostate cancer: from preclinical research to translational oncology.
    Maugeri-Saccà M; Coppola V; Bonci D; De Maria R
    Cancer J; 2012; 18(3):253-61. PubMed ID: 22647362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The significance of LMO2 expression in the progression of prostate cancer.
    Ma S; Guan XY; Beh PS; Wong KY; Chan YP; Yuen HF; Vielkind J; Chan KW
    J Pathol; 2007 Feb; 211(3):278-85. PubMed ID: 17167821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.